Opinion|Videos|April 17, 2024
Biomarker Testing Challenges in HER2-mutated NSCLC
Experts on HER2-mutated non–small cell lung cancer provide clinical insights on biomarker testing challenges and the role of reflex testing.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.
TRE-515 earned fast track status in combination with KRAS inhibitors for G12C-mutated NSCLC after anti–PD-(L)1 therapy and platinum-based chemotherapy.
An NDA for zipalertinib in EGFR exon 20 insertion–positive NSCLC is being supported by phase 3 REZILIENT3 data.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.
Estelamari Rodriguez, MD, MPH, discusses the rationale, design, and practice implications of the phase 3 RELATIVITY-1093 trial in nonsquamous NSCLC.
Plinabulin plus docetaxel received fast track designation for pretreated nonsquamous NSCLC without actionable genomic alterations.
Faculty convened at an OncLive Scientific Interchange and Workshop to discuss individualized treatment and strategic sequencing in HER2-mutated NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
2
The OncFive: Top Oncology Articles for the Week of 9/27/2026
3
FDA Grants Fast Track Designation to TRE-515 Plus KRAS Inhibitors in Pretreated KRAS G12C+ NSCLC
4
FLORA-2 Updates at World Lung: Biomarker Analysis, Safety Follow-Up, and ctDNA Monitoring
5